CTI BioPharma (FRA:CEPS) Total Current Assets : €80.75 Mil (As of Mar. 2023)

View and export this data going back to 2007. Start your Free Trial

What is CTI BioPharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. CTI BioPharma's total current assets for the quarter that ended in Mar. 2023 was €80.75 Mil.

CTI BioPharma Total Current Assets Historical Data

The historical data trend for CTI BioPharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Total Current Assets Chart

CTI BioPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

72.51

32.02

44.66

60.52

93.83

CTI BioPharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Current Assets	Get a 7-Day Free Trial															93.78	101.57	97.90	93.83	80.75

CTI BioPharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

CTI BioPharma's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	75.462	+	14.525	+	0.692	+	3.151
	=	93.83

CTI BioPharma's Total Current Assets for the quarter that ended in Mar. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	55.116	+	21.442	+	0.726	+	3.463
	=	80.75

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

CTI BioPharma (FRA:CEPS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

CTI BioPharma's Liquidation Value for the quarter that ended in Mar. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	55.116	-	128.536	+	0.75 * 21.442	+	0.5 * 0.726
=	-56.98

CTI BioPharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CTI BioPharma (FRA:CEPS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121

Website

https://www.ctibiopharma.com

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (FRA:CEPS) Headlines

No Headlines